Dendritic cell transfer for cancer immunotherapy

Liwei Zhao; Shuai Zhang; Oliver Kepp; Guido Kroemer; Peng Liu

doi:10.1016/bs.ircmb.2022.03.003

Dendritic cell transfer for cancer immunotherapy

Liwei Zhao, Shuai Zhang, Oliver Kepp, Guido Kroemer, Peng Liu

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

14 Citations (Scopus)

Abstract

Dendritic cells (DCs) play a major role in cancer immunosurveillance as they bridge innate and adaptive immunity by detecting tumor-associated antigens and presenting them to T lymphocytes. The adoptive transfer of antigen loaded DCs has been proposed as an immunotherapeutic approach for the treatment of various types of cancer. Nevertheless, despite promising preclinical data, the therapeutic efficacy of DC transfer is still deceptive in cancer patients. Here we summarize recent findings in DC biology with a special focus on the development of actionable therapeutic strategies and discuss experimental and clinical approaches that aim at improving the efficacy of DC-based immunotherapies, including, but not limited to, optimized DC production and antigen loading, stimulated maturation, the co-treatment with additional immunotherapies, as well as the inhibition of DC checkpoints.

Original language	English
Title of host publication	Adoptive Cell Transfer
Editors	Fernando Aranda, Pedro Berraondo, Lorenzo Galluzzi
Publisher	Elsevier Inc.
Pages	33-64
Number of pages	32
ISBN (Print)	9780323993999
DOIs	https://doi.org/10.1016/bs.ircmb.2022.03.003
Publication status	Published - 1 Jan 2022

Publication series

Name	International Review of Cell and Molecular Biology
Volume	370
ISSN (Print)	1937-6448

Keywords

CRISPR
Checkpoint blockade
Gene editing
Immunogenic cell death
iniDC

Access to Document

10.1016/bs.ircmb.2022.03.003

Cite this

@inbook{11874d490adc4bbfa7176bd2ac1d4e05,

title = "Dendritic cell transfer for cancer immunotherapy",

abstract = "Dendritic cells (DCs) play a major role in cancer immunosurveillance as they bridge innate and adaptive immunity by detecting tumor-associated antigens and presenting them to T lymphocytes. The adoptive transfer of antigen loaded DCs has been proposed as an immunotherapeutic approach for the treatment of various types of cancer. Nevertheless, despite promising preclinical data, the therapeutic efficacy of DC transfer is still deceptive in cancer patients. Here we summarize recent findings in DC biology with a special focus on the development of actionable therapeutic strategies and discuss experimental and clinical approaches that aim at improving the efficacy of DC-based immunotherapies, including, but not limited to, optimized DC production and antigen loading, stimulated maturation, the co-treatment with additional immunotherapies, as well as the inhibition of DC checkpoints.",

keywords = "CRISPR, Checkpoint blockade, Gene editing, Immunogenic cell death, iniDC",

author = "Liwei Zhao and Shuai Zhang and Oliver Kepp and Guido Kroemer and Peng Liu",

note = "Publisher Copyright: {\textcopyright} 2022 Elsevier Inc.",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/bs.ircmb.2022.03.003",

language = "English",

isbn = "9780323993999",

series = "International Review of Cell and Molecular Biology",

publisher = "Elsevier Inc.",

pages = "33--64",

editor = "Fernando Aranda and Pedro Berraondo and Lorenzo Galluzzi",

booktitle = "Adoptive Cell Transfer",

}

TY - CHAP

T1 - Dendritic cell transfer for cancer immunotherapy

AU - Zhao, Liwei

AU - Zhang, Shuai

AU - Kepp, Oliver

AU - Kroemer, Guido

AU - Liu, Peng

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Dendritic cells (DCs) play a major role in cancer immunosurveillance as they bridge innate and adaptive immunity by detecting tumor-associated antigens and presenting them to T lymphocytes. The adoptive transfer of antigen loaded DCs has been proposed as an immunotherapeutic approach for the treatment of various types of cancer. Nevertheless, despite promising preclinical data, the therapeutic efficacy of DC transfer is still deceptive in cancer patients. Here we summarize recent findings in DC biology with a special focus on the development of actionable therapeutic strategies and discuss experimental and clinical approaches that aim at improving the efficacy of DC-based immunotherapies, including, but not limited to, optimized DC production and antigen loading, stimulated maturation, the co-treatment with additional immunotherapies, as well as the inhibition of DC checkpoints.

AB - Dendritic cells (DCs) play a major role in cancer immunosurveillance as they bridge innate and adaptive immunity by detecting tumor-associated antigens and presenting them to T lymphocytes. The adoptive transfer of antigen loaded DCs has been proposed as an immunotherapeutic approach for the treatment of various types of cancer. Nevertheless, despite promising preclinical data, the therapeutic efficacy of DC transfer is still deceptive in cancer patients. Here we summarize recent findings in DC biology with a special focus on the development of actionable therapeutic strategies and discuss experimental and clinical approaches that aim at improving the efficacy of DC-based immunotherapies, including, but not limited to, optimized DC production and antigen loading, stimulated maturation, the co-treatment with additional immunotherapies, as well as the inhibition of DC checkpoints.

KW - CRISPR

KW - Checkpoint blockade

KW - Gene editing

KW - Immunogenic cell death

KW - iniDC

UR - http://www.scopus.com/inward/record.url?scp=85133333649&partnerID=8YFLogxK

U2 - 10.1016/bs.ircmb.2022.03.003

DO - 10.1016/bs.ircmb.2022.03.003

M3 - Chapter

C2 - 35798506

AN - SCOPUS:85133333649

SN - 9780323993999

T3 - International Review of Cell and Molecular Biology

SP - 33

EP - 64

BT - Adoptive Cell Transfer

A2 - Aranda, Fernando

A2 - Berraondo, Pedro

A2 - Galluzzi, Lorenzo

PB - Elsevier Inc.

ER -

Dendritic cell transfer for cancer immunotherapy

Abstract

Publication series

Keywords

Access to Document

Other files and links

Cite this